0 citations
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Journal of Clinical Oncology1996Vol. 14(4), pp. 1128–1135
Citations Over TimeTop 1% of 1996 papers
Mace L. Rothenberg, John R. Eckardt, John G. Kuhn, Howard A. Burris, J. NELSON, Susan G. Hilsenbeck, G I Rodriguez, Allison Thurman, Lon Smith, S. Gail Eckhardt, Geoffrey R. Weiss, Gary Elfring, David Rinaldi, Larry J. Schaaf, Daniel D. Von Hoff
Abstract
Irinotecan has significant single-agent activity against colorectal cancer that has progressed during or shortly after treatment with 5-FU-based chemotherapy. The incidence of severe diarrhea is reduced by using a starting dose of irinotecan 125 mg/m2 and by initiating loperamide at the earliest signs of diarrhea. These results warrant further clinical evaluation to define the role of irinotecan in the treatment of individuals with colorectal cancer.
Related Papers
- → Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial(2010)52 cited
- → UGT1A1*28 Genotype Predicts Gastrointestinal Toxicity in Patients Treated With Intermediate-Dose Irinotecan(2009)34 cited
- → Irinotecan and colorectal cancer: the role of p53, VEGF-C and α-B-crystallin expression(2009)14 cited
- → Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients(2001)56 cited
- → Comprehensive genetic definition of susceptibility to toxic side effects of irinotecan in mice.(2015)